{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:14:23Z","timestamp":1788243263210,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-cyclophosphamide (PTCy)-based GVHD prophylaxis has shown significant success in haploidentical transplants. The potential of PTCy in adult umbilical blood transplantation (UCBT) remains unclear due to concerns about engraftment, given the limited number of CD34+ cells. This study aimed to explore the preliminary safety and efficacy of a reduced-intensity PTCy (RI-PTCy) in single-unit UCBT in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 52 adult patients who underwent a single-unit UCBT were included in this pilot study. Patients were divided into three groups based on GVHD prophylaxis regimens: No PTCy (n=30), 100 mg RI-PTCy (n=15), and 400 mg RI-PTCy (n=7). Safety and efficacy were investigated post-transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median times for neutrophil engraftment were 15 days (range, 12\u201327 days) in the No PTCy group, 16 days (range, 13\u201325 days) in the 100 mg RI-PTCy group, and 18 days (range, 15\u201324 days) in the 400 mg RI-PTCy group. Platelet engraftment occurred at 30 days (range, 21\u201377 days), 32 days (range, 18\u201340 days), and 31 days (range, 25\u201342 days), respectively. By day +100, the RI-PTCy groups had a significantly lower cumulative incidence of grade II-IV aGVHD than the No PTCy group. The cumulative incidence of grade II-IV aGVHD was 30.0% (95% CI, 13.6%-46.4%) in the No PTCy group, compared with 6.7% (95% CI, 0%-19.3%) in the RI-PTCy 100 mg group and 0% in the RI-PTCy 400 mg group (P\u00a0= .044). Notably, the 400 mg RI-PTCy group presents a higher incidence of 28-day bloodstream infection. Moreover, the estimated 1-year GRFS were 53.3% (95% CI, 34.3%-69.1%), 71.1% (95% CI, 39.4%-88.3%), and 100.0% in the No PTCy group, the 100 mg and 400 mg RI-PTCy groups (P\u00a0= .059).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RI-PTCy appears promising as a GVHD prophylaxis strategy in this exploratory pilot cohort; these hypothesis-generating findings warrant validation in larger prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1922972","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:25:55Z","timestamp":1788240355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced-intensity post-cyclophosphamide-based graft-versus-host disease prophylaxis for umbilical cord blood transplantation: a single-center pilot study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuntian","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimei","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanchen","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjun","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxin","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.005694","article-title":"Cord blood transplantation: state of the art","volume":"94","author":"Gluckman","year":"2009","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jtct.2024.11.011","article-title":"Comparison of nonrelapse mortality after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide versus single umbilical cord blood transplantation in hematologic disease","volume":"31","author":"Harada","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002257","article-title":"Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation","volume":"4","author":"Tang","year":"2020","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02729-5","article-title":"Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia","volume":"61","author":"Yanada","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03801-z","article-title":"Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation","volume":"98","author":"Yoshida","year":"2019","journal-title":"Ann Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05952-0","article-title":"Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease","volume":"104","author":"Kujawska","year":"2025","journal-title":"Ann Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/0963689720964771","article-title":"Haploidentical hematopoietic stem cell transplantation versus umbilical cord blood transplantation in hematologic Malignancies: a systematic review and meta-analysis","volume":"29","author":"Wu","year":"2020","journal-title":"Cell Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101096","article-title":"PTCy: The \"new\" standard for GVHD prophylaxis","volume":"62","author":"Bacigalupo","year":"2023","journal-title":"Blood Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy - a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1186\/s12885-022-10309-9","article-title":"Impact of posttransplant cyclophosphamide on the outcome of patients undergoing unrelated single-unit umbilical cord blood transplantation for pediatric acute leukemia","volume":"22","author":"Li","year":"2022","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0382-3","article-title":"Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic Malignancies: a prospective, phase II study","volume":"54","author":"Yang","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.01.020","article-title":"Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease","volume":"21","author":"Bradstock","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014879","article-title":"Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation","volume":"9","author":"Hyder","year":"2025","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.09.030","article-title":"Optimized timing of post-transplantation cyclophosphamide in MHC-haploidentical murine hematopoietic cell transplantation","volume":"26","author":"Wachsmuth","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06490-z","article-title":"Romiplostim versus recombinant human thrombopoietin in umbilical cord blood transplantation: a single-center retrospective study","volume":"104","author":"Ding","year":"2025","journal-title":"Ann Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jtct.2021.02.033","article-title":"Phase I dose-finding, safety, and tolerability trial of romiplostim to improve platelet recovery after UCB transplantation","volume":"27","author":"Christakopoulos","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180621","article-title":"Efficacy and safety of avatrombopag in the treatment of thrombocytopenia after umbilical cord blood transplantation","volume":"138","author":"Huang","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116048","article-title":"Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation","volume":"62","author":"Pasvolsky","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1038\/s41467-021-24412-1","article-title":"Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-026-02817-0","article-title":"Chronic graft-versus-host disease: current situation and unmet needs - a European position statement","volume":"61","author":"Malard","year":"2026","journal-title":"Bone Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101092","article-title":"Does PTCY increase the risk of infections","volume":"62","author":"Mikulska","year":"2023","journal-title":"Blood Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jcyt.2023.10.008","article-title":"Endothelial activation and stress index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis","volume":"26","author":"Escribano-Serrat","year":"2024","journal-title":"Cytotherapy"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.289205","article-title":"Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms","volume":"110","author":"Senapati","year":"2025","journal-title":"Haematologica"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1922972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:25:56Z","timestamp":1788240356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1922972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1922972"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1922972","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1922972"}}